Recommended regimens include carboplatin–paclitaxel, cisplatin–doxorubicin, cisplatin–doxorubicin–paclitaxel, carboplatin–docetaxel, carboplatin–paclitaxel–bevacizumab, ifosfamide–paclitaxel or cisplatin–ifosfamide (for carcinosarcoma), carboplatin–paclitaxel–trastuzumab (for HER2-positive serous carcinoma), and everolimus–letrozole (for endometrioid histology). Here, ERBB2 is linked to serous adenocarcinoma.